Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial
Clicks: 5
ID: 317629
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
1.2
/100
5 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #30 of 206 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 206 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives To describe the prevalence and extent of whole body (WB)-MRI detected joint disease features and their response to therapy in patients with early, active PsA. Methods Newly diagnosed PsA patients (treatment-naïve), recruited in GOLMePsA randomized trial (methotrexate plus golimumab and steroids, GOLMTX vs methotrexate plus steroids, PBOMTX), underwent a multi-joint MRI protocol (baseline; week 24 [primary outcome] and week 36). The validated WIPE (peripheral joints and entheses); HIMRISS, KIMRISS (hip and knee); HEMRIS (heel); and CANDEN and SPARCC (sacroiliac joints (SIJs), spine) scores were recorded. Exploratory estimates of difference or ratios (with confidence intervals - CI; 75-95%) between groups at weeks 24 and 36, were obtained using multiple binary logistic or quantile (median) regression. Results Overall, 93 paired scans from 31 participants (median symptom duration 10.5 months; IQR 4.2-18.3; absolute range 1.8-197.7; 68% polyarticular) were included. Baseline scores showed widespread low intensity inflammation in peripheral tissues (median MRI-WIPE score: 37 – CI 19.0-55.0). SIJs and spine inflammation (SPARCC score ≥2) was seen in 25.8% (10/31) and 32.3% (10/31), respectively. Participants achieved median MRI-WIPE delta (the difference between time-points) of -10 at week 24 and -7 at week 36 in the GOLMTX and -6 and -9 in PBOMTX arms respectively. No differences between treatment groups were observed. Conclusions In this exploratory analysis, WB-MRI identified widespread although low intensity inflammation in peripheral joints and enthesis with improvements seen at 24 and 36 weeks and no meaningful differences between treatment arms. Axial abnormalities were seen in one third of patients at baseline. Clinical Trial registration Clinicaltrials.gov; NCT04108468
| Reference Key |
openalex_W7165042176
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Gabriele De Marco, Walter P. Maksymowych, Mikkel Østergaard, Iris Eshed, Ai Lyn Tan, Philip Helliwell, Dennis McGonagle, E. Hensor, Helena Marzo‐Ortega |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag308
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.